ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lactylation (H3K18la), induced by GEM-driven lactate accumulation, as a key epigenetic mechanism of chemoresistance. H3K18la functions as a transcriptional activator of ribosomal protein L11(RPL11) Elevated RPL11 establishes a dual, compartmentalized pro-survival program: in the cytoplasm, RPL11 binds and stabilizes eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) to enhance global protein synthesis; in the nucleus, RPL11 serves as a noncanonical transcriptional coactivator of (ADP-ribose) polymerase 14 (PARP14), augmenting DNA damage repair and attenuating GEM cytotoxicity. Pharmacologic or genetic inhibition of lactate production or RPL11 expression synergizes with GEM to overcome resistance and suppress PDAC progression in xenograft models. These findings define a lactate-H3K18la-RPL11axis that couples metabolic and epigenetic remodeling to translational control and genome maintenance, revealing actionable vulnerabilities in PDAC chemoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.